Gemin X Raises $8 Million

Gemin X Pharmaceuticals Inc., an oncology drug developer with offices in both Malvern, Pa. and Montreal, has raised $8 million in Series E funding. Return backers Caxton Advantage Life Sciences Fund and Sanderling Venture Partners co-led the round. The company had announced a $16 million Series D round back in April, which included a $4 million investor option.

North AmericaUSBriefs